3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
81
Precursor Cell Lymphoblastic Leukemia-Lymphoma
68
Myelodysplastic Syndromes
65
Lymphoma, Non-Hodgkin
51
Leukemia, Lymphocytic, Chronic, B-Cell
51
Hodgkin Disease
47
Leukemia
44
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
41
Multiple Myeloma
40
Lymphoma, Mantle-Cell
37
Lymphoma, Follicular
36
Myeloproliferative Disorders
34
Lymphoma
34
Lymphoma, B-Cell, Marginal Zone
33
Burkitt Lymphoma
32
Lymphoma, Large B-Cell, Diffuse
29
Leukemia, Myelomonocytic, Chronic
29
Hematologic Neoplasms
25
Congenital Abnormalities
24
Lymphoma, Large-Cell, Immunoblastic
21
Leukemia, Myeloid, Accelerated Phase
21
Leukemia, Biphenotypic, Acute
20
Primary Myelofibrosis
19
Leukemia, Myeloid, Chronic-Phase
19
Anemia, Refractory, with Excess of Blasts
19
Waldenstrom Macroglobulinemia
18
Blast Crisis
17
Dendritic Cell Sarcoma, Interdigitating
16
Lymphoma, Large-Cell, Anaplastic
15
Leukemia, Prolymphocytic
15
Interventions
Etoposide
3
Dexamethasone
2
Cyclophosphamide
2
Alemtuzumab
2
tocilizumab
1
sintilimab
1
pegaspargase
1
Whole-Body Irradiation
1
Vincristine
1
Prednisone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Methotrexate
1
Gemcitabine
1
EPOCH protocol
1
Doxorubicin
1
Cytarabine
1
Calcium Dobesilate
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphohistiocytosis, Hemophagocytic
×
Whole-Body Irradiation
×
Clear all
NCT00368355
2020-01-21
MOHEL
Baylor College of Medicine
Phase 2
Completed
46 enrolled
12 charts